ManaliKamdarMD

PubMed

• Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following fail...
  Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Future Oncology. 2024 Mar 28
• 1 citations
  Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.
  Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R ...> ;Blood. 2024 Jan 22
• Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.
  Davila, E., Bradeen, X., Abbott, D., Zain, J., Kamdar, M., Neuwelt, A., Jasem, J., Porcu, P., Major, A., Major, A., Haverkos, B., Major, A., Bair, S., Smith, C.> ;Blood Advances. 2024 Feb 13
• 1 citations
  Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
  Steiner, R., Hwang, S., Khurana, A., Habermann, T., Epperla, N., Annunzio, K., Allen, P., Baird, K., Paulino, D., Alderuccio, J., Lossos, I., David, K., Evens, A., Pan...> ;Blood Advances. 2023 Dec 26
• Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...
  Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
• Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter...
  Michael Wang, Tanya Siddiqi, Leo I Gordon, Manali Kamdar, Matthew Lunning, Alexandre V Hirayama, Jeremy S Abramson, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Chara...> ;Journal of Clinical Oncology. 2024 Apr 1
• 3 citations
  Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
  Budde, L., Olszewski, A., Assouline, S., Lossos, I., Diefenbach, C., Kamdar, M., Ghosh, N., Modi, D., Sabry, W., Naik, S., Mehta, A., Nakhoda, S., Smith, S., Dorritie,...> ;Nature Medicine. 2024 Jan 1
• 1 citations
  Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
  Major, A., Kamdar, M.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
• 4 citations
  High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
  Zayac, A., Landsburg, D., Hughes, M., Bock, A., Nowakowski, G., Ayers, E., Girton, M., Hu, M., Beckman, A., Li, S., Medeiros, L., Chang, J., Stepanovic, A., Kurt, H., ...> ;Blood Advances. 2023 Nov 14
• Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia.
  Manali Kamdar> ;Lancet. 2023 Aug 19
• 4 citations
  Cellular therapy in lymphoma.
  Anna Sureda, Pieternella J Lugtenburg, Marie José Kersten, Marion Subklewe, Anne Spanjaart, Nirali N Shah, Lucila N Kerbauy, Clarie Roddie, Elise R A Pennings, Carolin...> ;Hematological Oncology. 2023 Jun 29
• 3 citations
  Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of re...
  Charlotte B Wagner, Ken Boucher, Adrienne Nedved, Ivana N Micallef, Sanjal Desai, Haris Hatic, Gaurav Goyal, Erin Zacholski, Amanda Fegley, Audrey M Sigmund, David A B...> ;Haematologica. 2023 Nov 1
• 5 citations
  Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
  Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali K Kamdar, Bradley M Haverkos, James Godfrey, Melissa A Babcook, Timothy J V...> ;Blood Advances. 2023 Aug 22
• 1 citations
  A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
  Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko, Jason T Romancik, Manali Kamdar, I Brian Greenwell, Brian T Hess, Krista M Isaac, Craig A Portell, Alex Mejia Garcia...> ;Blood Advances. 2023 Jul 11
• 13 citations
  A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.
  Geoffrey Shouse, Andy Kaempf, Max J Gordon, Andy Artz, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven M Bair, Agrima Mian, Lindsey A Fitzgerald, Amneet Bajwa, ...> ;Blood Advances. 2023 Jul 25
• 1 citations
  Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.
  Cassandra Duarte, Manali Kamdar> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2023 Jan 1
• 60 citations
  Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
  Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Blood. 2023 Apr 6
• 8 citations
  A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
  Mark A Dawson, Gautam Borthakur, Brian J P Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T Vogl, Daniel A Pollyea, Faith E Davies, Gareth J M...> ;Clinical Cancer Research. 2023 Feb 16
• 3 citations
  A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
  Matthew J Cortese, Wei Wei, Sebastian Cerdeña, Marcus P Watkins, Marissa Olson, Gray Jodon, Jeff Kaiser, Bradley Haverkos, Mitchell E Hughes, Esin Namoglu, Natalie S G...> ;Leukemia & Lymphoma. 2023 Jan 1
• 2 citations
  Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy.
  Gray Jodon, Meryl D Colton, Diana Abbott, Anthony Cai, Bradley Haverkos, Rustain Morgan, Manali Kamdar> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jan 1
• 5 citations
  Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
  Jeremy S Abramson, Patrick B Johnston, Manali Kamdar, Sami Ibrahimi, Koji Izutsu, Jon Arnason, Bertram Glass, Pim Mutsaers, Matthew Lunning, Julia Braverman, Fei Fei L...> ;Blood Advances. 2022 Dec 13
• 19 citations
  Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
  Meghan C Thompson, Rosemary A Harrup, Catherine C Coombs, Lindsey E Roeker, Jeffrey J Pu, Michael Y Choi, Paul M Barr, John N Allan, Martin Šimkovič, Lori Leslie, Joan...> ;Blood Advances. 2022 Aug 9
• 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review.
  Emily M Kudalkar, Changlee Pang, Mary M Haag, Daniel A Pollyea, Manali Kamdar, Gang Xu, Meng Su, Billie Carstens, Karen Swisshelm, Liming Bao> ;Molecular Cytogenetics. 2022 Jul 7
• 158 citations
  Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with r...
  Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Il...> ;Lancet. 2022 Jun 18
• 28 citations
  NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
  William G Wierda, Jennifer Brown, Jeremy S Abramson, Farrukh Awan, Syed F Bilgrami, Greg Bociek, Danielle Brander, Asher A Chanan-Khan, Steve E Coutre, Randall S Davis...> ;Journal of the National Comprehensive Cancer Network. 2022 Jun 1
• Join now to see all

Abstracts/Posters

• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
  Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
  Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma
  Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for Intern...
  Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocy...
  Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Res... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Sin... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018